PHIRE! - 120 Capsules

PHIRE!™ Xtreme Metabolic Fat-Loss Technology

PHIRE!™ Xtreme Metabolic Fat-Loss Technology. PHIRE!™ is a revolutionary pharmaceutical-grade fat loss formula specifically designed to boost your metabolism and heighten your energy levels. PHIRE!™’s scientifically designed mixture of ingredients are brought together to eradicate undesired fat where it matters most! Ground breaking ingredients such as Evodiamine and Forskolin have been shown to utilize stored body fat for energy, naturally increasing the body’s metabolism. In addition, PHIRE!™ is formulated with Caffeine, Yohimbe and Tyrosine to increase energy, mental alertness and focus. Stop spinning your wheels with inefficient fat loss products and upgrade to Axis Labs® PHIRE!™, the Xtreme Metabolic that will help you expose your hardest core ever!

PHIRE!™ Highlights:
• Powerful Source of Energy and Increases Mental Alertness and Focus
• Decreases Fatigue
• Maintains Muscle Tone
• Utilizes Stored Body Fat for Fuel
• Optimizes Cardiovascular Function [increases capillary dilation]
• Suppresses Appetite
• Supports Energy Metabolism and Helps the Body with the Breakdown of Fat and Carbohydrates
• Supports Thyroid Production to Ramp Up Metabolism
• Enhanced Feeling of Well Being
• Enhanced Insulin Secretion and Sensitivity

What is PHIRE!™ made up of that makes it such a powerful fat burning supplement?

Evodiamine
Evodiamine is a bioactive alkaloid extract from a plant called Evodiae Fructus. This is a Chinese herb named Wu-Chu-Yu that Chinese herbalists have used for centuries as a weight loss supplement. Evodiamine is related to capsaicin or the spicy flavor of peppers. It acts as a vanilloid receptor agonist, and can enhance lipolytic (breakdown of fat) activity, enhance insulin secretion and sensitivity.

Interestingly enough, Evodiamine can raise the body’s skin temperature while simultaneously decreasing core temperature, similar to a hypothermic state. Studies have shown that this is an effective process to burn calories and fat for energy while the body increases its temperature.

Forskolin
Froskolin is a diterpene found in the root of an Indian plant called Coleus Forskohlii (part of the mint family of plants). In the body, Forskolin activates an enzyme that raises levels of a key cell-regulating substance called cAMP (cyclic adenosine monophosphate). Increased cellular cAMP levels cause numerous physiological and biochemical effects such as increased insulin secretion, increased thyroid function (and therefore metabolic rate), reduced adipose assimilation and increased lipolysis (the breakdown of fats). Forskolin can also increase blood flow and capillary dilation.

Thiamine
Thiamine helps support energy metabolism and assists the body with the breakdown of fat, and carbohydrates. Every cell of the body requires vitamin B1 to form ATP from the break down of fat and carbohydrates. Thiamine keeps your mucous membranes healthy and is essential for nervous system, cardiovascular and muscular function, and it also helps maintain muscle tone.

Niacin
Niacin helps support energy metabolism and assists the body with the breakdown of fat, carbohydrates. Niacin helps fuel your body by converting blood sugar into energy, and assists in the release of energy from the metabolism of carbohydrates, fats, and proteins. Niacin is also necessary for the synthesis of secondary sex hormones.

Yohimbine
Yohimbine, an alkaloid, is the primary active ingredient of yohimbe. Yohimbine increases the amount of adrenergic activity in the body, increasing levels of norepinephrine and stimulation of the central nervous system. In addition, Yohimbine has shown to increase lipolysis (the breaking down of fat). Yohimbine has also shown to be an appetite suppressant, potentially reducing caloric intake. It has also been shown to enhance insulin secretion and sensitivity.

Caffeine
Caffeine has Thermogenic properties and increases lipolysis (fat break down). Caffeine can suppress appetite, decrease fatigue, and increase alertness and work capacity, which can be very beneficial for endurance exercise. Caffeine acts as a stimulant and has a synergistic effect with norepinephrine and other catecholamines like ephedrine and yohimbine. Thermogenic and stimulant effects can be greatly increased through the synergistic effect of caffeine.

L-Tyrosine
L-Tyrosine is essential amino acid that is a building block of protein and is necessary for maintaining proper brain function. L-Tyrosine is a precursor to the adrenal hormones norepinephrine, epinephrine, dopamine and to thyroid hormones. Because L-Tyrosine is a precursor of dopamine, supplementing with L-Tyrosine may increase feelings of well being, heighten mental alertness and offset physical and mental fatigue. L-Tyrosine has also show to suppress appetite, potentially reducing caloric intake.

Demand more from your thermogenic. Demand Axis Labs® PHIRE!™

Supplement Facts Serving Size: 2 Capsules Servings per Container: 60
	Amount Per Serving	%DV*
Vitamin B1 (Thiamine)	25mg	1666%
Vitamin B3 (Niacin)	25mg	125%
Caffeine Anhydrous	200mg	†
Yohimbe (3% Yohimbine)	100mg	†
Evodiamine 98%	50mg	†
Coleus Forskohli (40% Forskolin)	50mg	†
L-Tyrosine	50mg	†
* Daily value (DV) are based on a 2000 calorie diet † Daily value (DV) not established

Other Ingredients: Dicalcium Phosphate, Gelatin, purified water, Magnesium Stearate, Silica.

Directions: As a dietary supplement, take 1-2 capsules, 30 minutes prior to breakfast and 1-2 capsules in the early afternoon. Do not take 6 hours prior to bed because PHIRE!™ may interfere with sleep. For best results, use in conjunction with a reduced caloric diet and cardiovascular exercise program.

Store in a cool place. Protect from heat, light and moisture.

WARNING: KEEP OUT OF REACH OF CHILDREN. Not for use by individuals under the age of 18 or elderly. Consult a physician before using this or any dietary supplements. Do not use if pregnant, nursing or chronically ill. This product is not intended for individuals who are at risk of or have been treated for high blood pressure, heart disease, thyroid disease, depression or other psychiatric condition, renal disease, reoccurring headaches, spasms, has asthma or taking asthma medication or if your are using a MAO inhibitor.

Manufactured with pride in the USA.
PHIRE™ is a registered trademark of Axis Labs®.

* These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

REFRENCES:
Evodiamine
1) Kobayashi, Y., Y. Nakano, M. Kizaki, K. Hoshikuma, Y. Yokoo and T. Kamiya (2001). Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 67(7): 628-33.
2) Komatsu, K., K. Wakame and Y. Kano (1993). Pharmacological properties of galenical preparation. XVI. Pharmacokinetics of evodiamine and the metabolite in rats. Biol Pharm Bull 16(9): 935-8.
3) Pearce LV, Petukhov PA, Szabo T, Kedei N, Bizik F, Kozikowski AP, Blumberg PM. (2004). Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol Chem. Aug 21;2(16):2281-6. Epub 2004 Jul 27.
Tyrosine
1) Banderet, LE, and Lieberman HR. (1989). Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull 22: 759-762.
2) Gelenberg AJ, Gibson CJ, Wojcik JD. (1982). Neurotransmitter precursors for the treatment of depression. Psychopharmacol Bull 18:7-18.
3) Harmer CJ, McTavish SF, Clark L, Goodwin GM, Cowen PJ. (2001). Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacology (Berl). Feb;154(1):105-11.
4) Lieberman, HR, Corkin S, Spring BJ, Wurtman RJ, and Growden JH. (1985). The effects of dietary neurotransmitter precursors on human behavior. Am J Clin Nutr 42: 366-370.
5) Roberts SA, Thorpe JM, Ball RO, Pencharz PB. (2001). Tyrosine requirement of healthy men receiving a fixed phenylalanine intake determined by using indicator amino acid oxidation. Am J Clin Nutr. Feb;73(2):276-82.
Caffeine
1) Kourtidou-Papadeli C, Papadelis C, Louizos AL, Guiba-Tziampiri O. (2002). Maximum cognitive performance and physiological time trend measurements after caffeine intake. Cogn Brain Res. May;13(3):407-15.
2) Papadelis C, Kourtidou-Papadeli C, Vlachogiannis E, Skepastianos P, Bamidis P, Maglaveras N, Pappas K. (2003). Effects of mental workload and caffeine on catecholamines and blood pressure compared to performance variations. Brain Cogn. Feb;51(1):143-54.
3) Plaskett CJ, Cafarelli E. (2001). Caffeine increases endurance and attenuates force sensation during submaximal isometric contractions. J Appl Physiol. Oct;91(4):1535-44.
Forskolin
1) Borea, P. A., K. Varani, A. Dalpiaz, A. Capuzzo, E. Fabbri and I. J. AP (1994). Full and partial agonistic behaviour and thermodynamic binding parameters of adenosine A1 receptor ligands. Eur J Pharmacol 267(1): 55-61.
2) Chaudhry, A. and J. G. Granneman (1991). Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat. Am J Physiol 261(2 Pt 2): R403-11.
3) Chaudhry, A. and J. G. Granneman (1997). Effect of hypothyroidism on adenylyl cyclase activity and subtype gene expression in brown adipose tissue. Am J Physiol 273(2 Pt 2): R762-7.
4) Dolgacheva, L. P., B. B. Abzhalelov, S. J. Zhang, V. P. Zinchenko and G. E. Bronnikov (2003). Norepinephrine induces slow calcium signalling in murine brown preadipocytes through the beta-adrenoceptor/cAMP/protein kinase A pathway. Cell Signal 15(2): 209-16.
5) Dubey MP, Srimal RC, Nityanand S, Dhawan BN. (1981). Pharmacological studies on coleonol, a hypotensive diterpene from Coleus forskohlii. J Ethnopharmacol Jan;3(1):1-13.
6) Hellstrom, L., S. Rossner, E. Hagstrom-Toft and S. Reynisdottir (1997). Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity--a metabolic predictor of weight loss in obese subjects. Int J Obes Relat Metab Disord 21(4): 314-20.
7) Ho, R. and Q. H. Shi (1982). Forskolin as a novel lipolytic agent. Biochem Biophys Res Commun 107(1): 157-64.
8) Honnor, R. C., G. S. Dhillon and C. Londos (1985). cAMP-dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady-state relationship with lipolytic and antilipolytic modulators. J Biol Chem 260(28): 15130-8.
9) Imbeault P, Tremblay A, Despres J, Mauriege P. (2000). Beta-adrenoceptor-stimulated lipolysis of subcutaneous abdominal adipocytes as a determinant of fat oxidation in obese men. Eur J Clin Invest Apr;30(4):290-6.
10) Imbeault, P., D. Prud'Homme, A. Tremblay, J. P. Despres and P. Mauriege (2000). Adipose tissue metabolism in young and middle-aged men after control for total body fatness. J Clin Endocrinol Metab 85(7): 2455-62.
11) Lofgren P, Hoffstedt J, Ryden M, Thorne A, Holm C, Wahrenberg H, Arner P. (2002). Major gender differences in the lipolytic capacity of abdominal subcutaneous fat cells in obesity observed before and after long-term weight reduction. J Clin Endocrinol Metab Feb;87(2):764-71.
12) Litosch, I., T. H. Hudson, I. Mills, S. Y. Li and J. N. Fain (1982). Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes. Mol Pharmacol 22(1): 109-15.
13) Malbon, C. C. and M. P. Graziano (1983). Adenosine deaminase normalizes cyclic AMP responses of hypothyroid rat fat cells to forskolin, but not beta-adrenergic agonists. FEBS Lett 155(1): 35-8.
14) Marians RC, Ng L, Blair HC, Unger P, Graves PN, Davies TF. (2002). Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc Natl Acad Sci U S A Nov 26;99(24):15776-81.
15) Ottosson, M., P. Lonnroth, P. Bjorntorp and S. Eden (2000). Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J Clin Endocrinol Metab 85(2): 799-803.
16) Scarpace, P. J., L. A. Baresi and J. E. Morley (1987). Modulation of receptors and adenylate cyclase activity during sucrose feeding, food deprivation, and cold exposure. Am J Physiol 253(6 Pt 1): E629-35.
17) Simon, E., M. T. Macarulla, A. Fernandez-Quintela, V. M. Rodriguez and M. P. Portillo (2005). Body fat-lowering effect of conjugated linoleic acid is not due to increased lipolysis. J Physiol Biochem 61(2): 363-9.
18) Zhang, S. R., Q. H. Shi and R. J. Ho (1983). Cyclic AMP-lowering mediator of insulin. J Biol Chem 258(10): 6471-6.
19) Zhang XP, Tada H, Wang Z, Hintze TH. (2002). cAMP signal transduction, a potential compensatory pathway for coronary endothelial NO production after heart failure. Arterioscler Thromb Vasc Biol Aug 1;22(8):1273-8.
Yohimbe
1) Currie PJ, Wilson LM. (1992). Yohimbine attenuates clonidine-induced feeding and macronutrient selection in genetically obese (ob/ob) mice. Pharmacol Biochem Behav. Dec;43(4):1039-46
2) Galitzky J, Lafontan M, Nordenstrom J, Arner P. (1993). Role of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human adipose tissue. J Clin Invest. May;91(5):1997-2003.
3) Galitzky J, Riviere D, Tran MA, Montastruc JL, Berlan M. (1990). Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers. Eur J Clin Pharmacol. 39(5):447-51.
4) Galitzky J, Taouis M, Berlan M, Riviere D, Garrigues M, Lafontan M. (1988). Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest. Dec;18(6):587-94
5) Gomez-Ambrosi J, Fruhbeck G, Aguado M, Milagro FI, Margareto J, Martinez AJ. (2001). Divergent effects of an alpha2-adrenergic antagonist on lipolysis and thermogenesis: interactions with a beta3-adrenergic agonist in rats. Int J Mol Med. Jul;8(1):103-9
6) Kucio C, Jonderko K, Piskorska D. (1991). Does yohimbine act as a slimming drug? Isr J Med Sci. Oct;27(10):550-6.
7) Le Corre P, Dollo G, Chevanne F, Le Verge R. (1999). Biopharmaceutics and metabolism of yohimbine in humans. Eur J Pharm Sci. Oct;9(1):79-84
8) Tam SW, Worcel M, Wyllie M. (2001). Yohimbine: a clinical review. Pharmacol Ther. Sep;91(3):215-43
Thiamine
1) Guy-Grand, B., G. Dorf, J. Duchier and P. Aimez (1972). Dietetics and nutrition in 1972. Rev Prat 22(6): 743-62.
2) Hobara, R., H. Kato and K. Sakamoto (1983). Effect of thiamine and thiamine levels on experimental alloxan induced diabetes mellitus. Jpn J Pharmacol 33(1): 27-31.
3) Kirchgessner, M., D. A. Roth-Maier, U. Heindl and F. J. Schwarz (1995). B-vitamins (thiamine, vitamin b6, pantothenic acid) in lean muscle tissue of growing cattle of the German Simmental breed under different feeding intensities. Z Lebensm Unters Forsch 201(1): 20-4.
4) Lemonnier, D., P. de Gasquet, S. Griglio, R. Naon, F. Reynouard and J. Tremolieres (1974). Effect of dietary vitamin B level on fat storage, adipose tissue cellularity and energy expenditure in rats and mice fed a high-fat diet. Nutr Metab 16(1): 15-29.
5) Mehlman, M. A., R. B. Tobin, M. M. Madappally and H. K. Hahn (1971). Mode of action of aspirin. Effect of dietary aspirin on mitochondrial pyruvate metabolism in normal and thiamine-deficient rats. J Biol Chem 246(6): 1618-22.
6) Muroyama, K., S. Murosaki, Y. Yamamoto, A. Ishijima and Y. Toh (2003). Effects of intake of a mixture of thiamin, arginine, caffeine, and citric acid on adiposity in healthy subjects with high percent body fat. Biosci Biotechnol Biochem 67(11): 2325-33.
7) Muroyama, K., S. Murosaki, Y. Yamamoto, H. Odaka, H. C. Chung and M. Miyoshi (2003). Anti-obesity effects of a mixture of thiamin, arginine, caffeine, and citric acid in non-insulin dependent diabetic KK mice. J Nutr Sci Vitaminol (Tokyo) 49(1): 56-63.
8) Rieder, H. P., W. Berger and R. Fridrich (1980). Vitamin status in diabetic neuropathy (thiamine, riboflavin, pyridoxin, cobalamin and tocopherol). Z Ernahrungswiss 19(1): 1-13.
Niacin
9) Carlson, L. A. and J. Ostman (1965). Inhibition Of The Mobilization Of Free Fatty Acids From Adipose Tissue In Diabetes. Ii. Effect Of Nicotinic Acid And Acetylsalicylate On Blood Glucose In Human Diabetics. Acta Med Scand 178: 71-9.
10) Gaion, R. M., L. Murari, L. Cima, P. Valenti and P. Da Re (1985). Antilipolytic activity of tiadenol-nicotinate in isolated fat cells: a comparison with its parent drugs. Drugs Exp Clin Res 11(6): 407-11.
11) Grunfeld, C. and J. K. Shigenaga (1984). Nicotinamide and other inhibitors of ADP-ribosylation block deoxyglucose uptake in cultured cells. Biochem Biophys Res Commun 123(2): 785-91.
12) Hotz, W. (1983). Nicotinic acid and its derivatives: a short survey. Adv Lipid Res 20: 195-217.
13) Howald, H. and J. Decombaz (1983). Nutrient intake and energy regulation in physical exercise. Experientia Suppl 44: 77-88.
14) Lee, H. M., R. M. Ellis and M. V. Sigal, Jr. (1961). Some insulin-like effects of nicotinic acid observed with isolated rat epididymal adipose tissue. Biochim Biophys Acta 49: 408-10.
15) Ostman, J. (1964). Effect Of Nicotinic Acid On The Fatty Acid Metabolism Of Adipose Tissue In Alloxan Diabetic Rats. Metabolism 13: 675-80.
16) Ostman, J. (1965). Inhibitory Effect Of Nicotinic Acid On Ffa Mobilization In Alloxan-Diabetic Rats. Ii. A Comparison Of The Effect Of Nicotinic Acid And Salicylate On The Fatty Acid Metabolism And Glucose Uptake By Adipose Tissue In Vitro. Acta Med Scand 177: 623-9.
17) Schnare, D. W., G. Denk, M. Shields and S. Brunton (1982). Evaluation of a detoxification regimen for fat stored xenobiotics. Med Hypotheses 9(3): 265-82.
18) Walldius, G. and G. Wahlberg (1985). Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis. Adv Exp Med Biol 183: 281-93.